Welcome to Dermbits! Watch short videos of KOLs answering your questions

thumbnail_dermbits-colorful.png

dermbits-colorful.png

Dermbits

MD, MPH

Are there any concerns with the use of IL-23 or IL-17 inhibitors in patients with a history of cutaneous squamous cell carcinoma (cSCC)?

Psoriasis

You. Based on the currently available data looking at skin cancer and IL 17 and IL 23 inhibitors, there is no safety concerns or substantial safety concerns when it comes to using IL 17 or IL 23 inhibitors in patients with a history of cutaneous squamous cell carcinoma, and even if that particular history can be quite recent. That being said, it is very important that we see our patients who have psoriasis on these biologic agents in person at least once a year to make sure that we do a full skin check. Oftentimes, for my patients who are well controlled, I see them actually twice a year, and I do a full skin check at every one of those visits. But I would say at least once a year. Full body skin check is very important to screen for skin cancer in these patients and.